Oncothyreon's (ONTY -12%) after Martin Shkreli questions the benefits of the company's lung...

|By:, SA News Editor

Oncothyreon's (ONTY -12%) after Martin Shkreli questions the benefits of the company's lung cancer drug Stimuvax. He asserts the drug is poorly designed, fails to improve lung cancer survival and is not likely to pass its phase III testing trials.